FOXM1 Facilitates NSCLC Tumorigenesis Through the Transcriptional Regulation of UBE2C
The FASEB Journal · 2025
DOI: 10.1096/fj.202502016r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Hongpeng Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, S…. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Carcinoma, Non-Small-Cell Lung, Ubiquitin-Conjugating Enzymes, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of China.
Abstract (Originalsprache)
Forkhead box M1 (FOXM1), a critical transcription factor, is implicated in tumorigenesis by regulating cell cycle progression, proliferation, and metastasis. Similarly, Ubiquitin‐conjugating enzyme 2C (UBE2C), a key component of the ubiquitin‐proteasome system, plays a pivotal role in mitotic progression and genomic stability. Aberrant overexpression of FOXM1 and UBE2C has been reported in various malignancies; however, their functional interplay in NSCLC remains poorly understood. In this study, we investigated the oncogenic roles of FOXM1 and UBE2C in NSCLC through in vitro and in vivo models, as well as clinical specimen analysis. Our findings demonstrate that FOXM1 transcriptionally upregulates UBE2C, thereby promoting NSCLC cell proliferation, invasion, and tumor progression via activation of oncogenic signaling pathways. Mechanistically, FAM64A stabilized FOXM1 expression, contributing to its pro‐tumorigenic effects on NSCLC progression. Furthermore, FOXM1/UBE2C axis disruption impairs tumor growth, highlighting its potential as a novel therapeutic target. This study provides new insights into the molecular mechanisms underlying NSCLC pathogenesis and suggests that targeting the FAM64A/FOXM1/UBE2C axis may offer an effective strategy for NSCLC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
- Institute of Thoracic Oncology, Fudan University, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Quality Assurance, Hainan Simcere Pharmaceutical Co., Ltd, Hainan, China.
- Department of Pathology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
ORCID-Profile: Tao Yu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of China
Zitieren
APA
Shi, H., Deng, H., Chen, B., Zhu, Y., & Yu, T. (2025). FOXM1 Facilitates NSCLC Tumorigenesis Through the Transcriptional Regulation of UBE2C. The FASEB Journal. https://doi.org/10.1096/fj.202502016r
Vancouver
Shi H, Deng H, Chen B, Zhu Y, Yu T. FOXM1 Facilitates NSCLC Tumorigenesis Through the Transcriptional Regulation of UBE2C. The FASEB Journal. 2025. doi:10.1096/fj.202502016r
BibTeX
@article{Shi2025,
author = {Shi, Hongpeng and Deng, Hua and Chen, Bing and Zhu, Yuyao and Yu, Tao},
title = {FOXM1 Facilitates NSCLC Tumorigenesis Through the Transcriptional Regulation of UBE2C},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202502016r}
}
EUVIMED